Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD19	Synonyms	B4, CVID3	Type of gene	protein-coding
Chromosome	16	Map location	16p11.2	dbXrefs
Description	CD19 molecule

Gene symbol	CD22	Synonyms	SIGLEC-2, SIGLEC2	Type of gene	protein-coding
Chromosome	19	Map location	19q13.12	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	CD22 molecule

GTO ID	GTC0466
Trial ID	NCT03825731
Disease	B-Cell Acute Lymphoblastic Leukemia
Altered gene	CD19\|CD22
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	GC022
Generation	2nd
Phase	Early_Phase1
Recruitment status	Unknown
Title	A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Year	2019
Country	China
Company sponsor	Hebei Yanda Ludaopei Hospital
Other ID(s)	PGC0003

Vector information

Vector	lentivirus
Construct	scFv-4-1BB-CD3ζ

Clinical Result

Cohort1: dose level 1

Administration route	None
Dosage	2.5~5E5 cells/kg
Pts	4
Age	Child, Adult, Older_Adult
Lymph depletion	Yes
Outcome	1/4(CR)
Adverse reactions	no any CAR-T-related severe events
References	DOI: 10.1182/blood-2019-126429

Cohort2: dose level 2

Administration route	None
Dosage	1~2.5E6 cells/kg
Pts	7
Age	Child, Adult, Older_Adult
Lymph depletion	Yes
Outcome	7/7(CR) at 15 days
Adverse reactions	no any CAR-T-related severe events
References	DOI: 10.1182/blood-2019-126429

Cohort3: dose level 3

Administration route	None
Dosage	3~5E6 cells/kg
Pts	5
Age	Child, Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	DOI: 10.1182/blood-2019-126429

Relationship Graph

Overview of Knowledge Graph